•Journal•ISSN: 2405-6308
Clinical and Translational Radiation Oncology
Elsevier BV
About: Clinical and Translational Radiation Oncology is an academic journal published by Elsevier BV. The journal publishes majorly in the area(s): Medicine & Radiation therapy. It has an ISSN identifier of 2405-6308. It is also open access. Over the lifetime, 643 publications have been published receiving 6494 citations. The journal is also known as: CTRO.
Topics: Medicine, Radiation therapy, Internal medicine, Cancer, Prostate cancer
Papers
More filters
Medical University of Vienna1, Aarhus University Hospital2, University Medical Center Utrecht3, Leiden University Medical Center4, University of Cambridge5, Institut Gustave Roussy6, Tata Memorial Hospital7, Oslo University Hospital8, Post Graduate Institute of Medical Education and Research9, University of Alberta10, Katholieke Universiteit Leuven11, Université de Montréal12, Netherlands Cancer Institute13
TL;DR: The EMBRACE II study is an interventional and observational multicentre study which aims to benchmark a high level of local, nodal and systemic control while limiting morbidity, using state-of-the-art treatment including an advanced target volume selection and contouring protocol for EBRT and brachytherapy, a multi-parametric brachyTherapy dose prescription protocol (clinical validation of dose constraints), and use of advanced external beam radiotherapy (EBRT) and IC/IS) techniques.
413 citations
TL;DR: The Elekta Unity MR-linac adaptive radiotherapy concept is explained and different methods for dose re-calculation and optimization are discussed, with full online re-planning being the most robust adaptive planning method for the Unity.
314 citations
TL;DR: The 0.35 T MR-Linac combines a 6MV linac with onboard MR imaging that provides superior soft-tissue contrast compared to X-ray IGRT and allows a fully integrated on-table adaptive workflow.
206 citations
TL;DR: This document summarises discussions around themes of infection prevention, rationalisation of workload and working practice in the presence of infection, as the global COVID-19 pandemic escalates.
176 citations
TL;DR: HPV-driven cancers have significantly better survival than traditional head and neck cancers and current treatments are reassessed to develop less toxic strategies with good oncological outcomes.
142 citations